Dynamic Susceptibility Contrast MR Imaging in Glioma : Review of Current Clinical Practice - 13/10/16

Doi : 10.1016/j.mric.2016.06.005

Jerrold L. Boxerman, MD, PhD ^a,^⁎ , Mark S. Shiroishi, MD ^b, Benjamin M. Ellingson, PhD ^c, Whitney B. Pope, MD, PhD ^d
^a Department of Diagnostic Imaging, Rhode Island Hospital, Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA
^b Department of Radiology, Keck School of Medicine, University of Southern California, 1520 San Pablo Street, Lower Level Imaging L1600, Los Angeles, CA 90033, USA
^c UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine at UCLA, 924 Westwood Boulevard, Suite 615, Los Angeles, CA 90024, USA
^d Department of Radiological Sciences, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, 1621 East, Los Angeles, CA 90095, USA

^∗Corresponding author.

Résumé

Dynamic susceptibility contrast (DSC) MR imaging, a perfusion-weighted MR imaging technique typically used in neuro-oncologic applications for estimating the relative cerebral blood volume within brain tumors, has demonstrated much potential for determining prognosis, predicting therapeutic response, and assessing early treatment response of gliomas. This review highlights recent developments using DSC-MR imaging and emphasizes the need for technical standardization and validation in prospective studies in order for this technique to become incorporated into standard-of-care imaging for patients with brain tumors.

Le texte complet de cet article est disponible en PDF.

Keywords : Dynamic susceptibility contrast MR imaging (DSC-MR imaging), Cerebral blood volume (CBV), High-grade glioma, Glioblastoma, Response assessment, Pseudoprogression, Pseudoresponse, Prognosis

Plan

Key points

Basic principles of dynamic susceptibility contrast–MR imaging

Applications of dynamic susceptibility contrast–MR imaging to brain tumors

Initial Diagnosis, Prognosis, and Predicting Efficacy of Therapy Before Treatment

Assessing Response to Therapy

Imaging protocols

Summary

Disclosure Statement: Dr Boxerman has nothing to disclose. Dr Shiroishi is a consultant to Bayer and Guerbet. Dr Ellingson is a consultant for Roche/Genentech, Agios, Celegene, Natvis, Tocagen, Northwest Biopharmaceuticals, Amgen, and Excelixis; he serves on the administration board for Roche and Agios and has a grant from the National Brain Tumor Society. Dr Pope is a consultant for Roche, Amgen, Tocagen and Celldex Therapeutics.

Export

Vol 24 - N° 4

P. 649-670 - novembre 2016 Retour au numéro

Article précédent

New State-of-the-Art and Cutting-Edge Advances in Brain Tumor Imaging
Rivka R. Colen

| Article suivant

Multiparametric Imaging Analysis : Magnetic Resonance Spectroscopy
O. Rapalino, E.M. Ratai

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Dynamic Susceptibility Contrast MR Imaging in Glioma : Review of Current Clinical Practice - 13/10/16

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL